ImmunityBio reaches preliminary settlement in shareholder derivative lawsuit

ImmunityBio, Inc.

Court preliminarily approved derivative settlement on July 29, 2025, with final hearing set for Nov 4, 2025.
Settlement requires ImmunityBio to adopt corporate governance reforms including a new independent director and enhanced compliance.
Attorneys' fees not to exceed $1.4 million will be paid by insurance; no monetary payment to shareholders.
Governance reforms include quarterly board updates on FDA/cGMP compliance and annual legal department reviews.
Settlement resolves derivative actions related to alleged oversight failures and misleading statements about Anktiva BLA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.